Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune diseases, today announced clinical trial data from the Phase I/IIa study of its lead programme IMCgp100, at the American Association for Cancer Research Annual Meeting 2015, in Philadelphia, USA.
from The Medical News http://ift.tt/1HLniAf
Our mission is to advice, and to make the people of the world healthier through the power of information.
No comments:
Post a Comment